Targeting ubiquitination for cancer therapies

被引:87
|
作者
Morrow, John Kenneth [1 ,2 ]
Lin, Hui-Kuan [3 ]
Sun, Shao-Cong [4 ]
Zhang, Shuxing [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Integrated Mol Discovery Lab, Houston, TX 77030 USA
[2] Univ Texas Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[4] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
关键词
cancer therapeutics; deubiquitinase; E3 ligase inhibition; high-throughput virtual screening; hot spots; in silico modeling; SCF complex; Skp2; inhibitors; small molecule inhibitors; ubiquitination; SMALL-MOLECULE INHIBITOR; ACTIVE PROTEASOME INHIBITOR; SINGLE-AGENT CARFILZOMIB; CELL-CYCLE ARREST; LIGASE CBL-B; MULTIPLE-MYELOMA; OPEN-LABEL; DEUBIQUITINASE INHIBITION; NEDD8-ACTIVATING ENZYME; UBC13-UEV1A INTERACTION;
D O I
10.4155/fmc.15.148
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.
引用
收藏
页码:2333 / 2350
页数:18
相关论文
共 50 条
  • [41] Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies
    Rinninella, Emanuele
    Raoul, Pauline
    Cintoni, Marco
    Palombaro, Marta
    Pulcini, Gabriele
    Gasbarrini, Antonio
    Mele, Maria Cristina
    MICROORGANISMS, 2021, 9 (07)
  • [42] Emerging therapies targeting castration-resistant prostate cancer
    Gkialas, Ioarmis K.
    Fragkoulis, Charalampos
    JOURNAL OF BUON, 2015, 20 (06): : 1389 - 1396
  • [43] Novel therapies targeting hypoxia mechanism to treat pancreatic cancer
    Luo, Wenhao
    Qiu, Jiangdong
    Zheng, Lianfang
    Zhang, Taiping
    CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (02) : 216 - 231
  • [44] Establishing cost-effectiveness of genetic targeting of cancer therapies
    Retel, Valesca P.
    Rutgers, E. J. Th
    Joore, M. A.
    van Harten, W. H.
    EJHP PRACTICE, 2008, 14 (06): : 52 - 54
  • [45] Time to hit pause on mitochondria-targeting cancer therapies
    Zhang, Xue
    Dang, Chi V.
    NATURE MEDICINE, 2023, 29 (1) : 29 - 30
  • [46] Development of cancer therapies targeting multimeric tyrosine kinase Fer
    Oneyama, Chitose
    Ebi, Hiromichi
    Taguchi, Ayumu
    CANCER SCIENCE, 2025, 116 : 1538 - 1538
  • [47] Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
    Devlies, Wout
    Handle, Florian
    Devos, Gaetan
    Joniau, Steven
    Claessens, Frank
    CANCERS, 2021, 13 (04) : 1 - 17
  • [48] Targeting SCF E3 Ligases for Cancer Therapies
    Liu, Jing
    Peng, Yunhua
    Zhang, Jinfang
    Long, Jiangang
    Liu, Jiankang
    Wei, Wenyi
    CULLIN-RING LIGASES AND PROTEIN NEDDYLATION: BIOLOGY AND THERAPEUTICS, 2020, 1217 : 123 - 146
  • [49] Potential Therapies Targeting Metabolic Pathways in Cancer Stem Cells
    Shen, Yao-An
    Chen, Chang-Cyuan
    Chen, Bo-Jung
    Wu, Yu-Ting
    Juan, Jiun-Ru
    Chen, Liang-Yun
    Teng, Yueh-Chun
    Wei, Yau-Huei
    CELLS, 2021, 10 (07)
  • [50] Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
    Levade, Marie
    Severin, Sonia
    Gratacap, Marie-Pierre
    Ysebaert, Loic
    Payrastre, Bernard
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2315 - 2322